New Hope for Cancer Immunotherapy: Targeting the CDA Gene
Researchers have identified a promising target for cancer immunotherapy. The team led by Professor Massimiliano Mazzone found that the CDA gene is highly expressed in cancers resistant to immunotherapy. By inhibiting this gene through either pharmacological means or genetic intervention they observed improved infiltration of T-cells which in turn enhanced the effectiveness of immunotherapy in treating pancreatic ductal adenocarcinoma (PDAC), a severe form of pancreatic cancer.
Research and Publication
The study as conducted by the VIB-KU Leuven Centre for Cancer Biology has been published in the prestigious journal Nature Cancer. This discovery offers a significant advancement in the field of cancer treatment particularly for cancers that have shown resistance to existing immunotherapy methods.
Current Immunotherapy Landscape
Immunotherapy treatments such as adoptive T-cell transfer, cancer vaccines and immune checkpoint blockade (ICB) are promising options for cancer patients. These treatments have shown high response rates and extended survival in certain types of cancer like melanoma, lung, and renal cancers. However, ICB has not been as effective in treating other tumours particularly colorectal cancer and PDAC.
Challenges in Treating PDAC
PDAC is one of the most aggressive and deadly cancers with a mere 5-year survival rate of 9%. In Belgium, pancreatic cancer was the 9th most common cancer in 2021 with 2,242 new cases. Most PDAC patients are diagnosed at advanced stages with metastasis to distant organs leaving less than 20% of patients eligible for surgery at diagnosis. Even among those who undergo surgery, many experience a relapse and most therapies including ICB have proven ineffective.
Implications of the Discovery
The identification of the CDA gene as a target for enhancing immunotherapy efficacy in PDAC represents a beacon of hope for improving outcomes in this challenging cancer. By focusing on this gene, researchers aim to develop more effective treatments that can potentially increase survival rates and provide a better quality of life for patients suffering from PDAC and other immunotherapy-resistant cancers.
Unveiling the Role of CDA in Immunotherapy Resistance
- Exploring CDA in Pancreatic Cancer: A research team led by Professor Massimiliano Mazzone at the VIB-KU Leuven Center for Cancer Biology is exploring ways to overcome immunotherapy resistance. In their latest study, co-authored by Tommaso Scolaro, Marta Manco, Mathieu Pecqueux, and Ricardo Amorim, the team examined the role of an enzyme called cytidine deaminase (CDA) in pancreatic ductal adenocarcinoma (PDAC).
- The Function and Impact of CDA: Professor Mazzone explained that CDA is an enzyme crucial for recycling parts of DNA and RNA. It also plays a role in deactivating certain cancer drugs which can reduce the effectiveness of these treatments. While it is widely recognized that CDA contributes to chemotherapy resistance its impact on immunotherapy resistance had not been investigated before this study. "We decided to take a closer look to determine if CDA is indeed a roadblock for treatments such as immune checkpoint blockade (ICB)," Mazzone stated.
The Significance of the Study
By focusing on CDA, the researchers aimed to understand its potential role in hindering immunotherapy. Their findings could lead to new strategies for making immunotherapy more effective for patients with PDAC a particularly aggressive and challenging form of cancer. This study represents a crucial step in identifying and targeting mechanisms of resistance thereby improving the prospects of successful cancer treatments.
Unravelling the Role of CDA in Immunotherapy Resistance for Pancreatic Cancer
Through an in-depth analysis of multiple datasets of pancreatic ductal adenocarcinoma (PDAC) tumours, both responsive and resistant to immune checkpoint blockade (ICB) treatment researchers uncovered the significant role of the enzyme cytidine deaminase (CDA). The study revealed that CDA in cancer cells leads to the production of uridine-diphosphate (UDP), a molecule that influences certain immune cells known as tumour-associated macrophages (TAMs). UDP essentially commandeers these TAMs converting them into immunosuppressive cells.
The Significance of TAMs in Tumor Progression
This finding is particularly important because TAMs constitute approximately 50% of the tumour mass and are commonly linked to tumour growth and progression. By hijacking TAMs, UDP promotes an environment that allows the tumour to evade the immune system thereby contributing to the resistance against immunotherapy.
Insights from the Research
Tommaso Scolaro, the first author of the research paper expressed the team's enthusiasm about the discovery. "Our study demonstrated that CDA indeed plays a role in immunotherapy resistance," Scolaro noted. This breakthrough led the researchers to assume that by inhibiting the gene responsible for CDA production, they could potentially diminish the immunosuppressive nature of PDAC tumours, making them less resistant to treatments like ICB.
Potential Implications for Cancer Treatment
This research represents a significant step towards improving the effectiveness of immunotherapy for PDAC, one of the most challenging cancers to treat. By targeting the mechanisms that allow tumours to resist treatment, scientists hope to develop new strategies that can enhance the body's immune response against cancer and also, offer new hope for patients with PDAC and other hard-to-treat cancers.
Inhibiting the CDA Gene: A New Hope for Resistant Cancers
As a crucial next step, the research team focused on ways to inhibit the CDA gene in cancer cells. By using both pharmacologic and genetic interventions, they successfully disrupted the interactions between CDA-expressing cancer cells and tumour-associated macrophages (TAMs). This disruption led to improved infiltration of T-cells and increased vulnerability to immunotherapy treatments in resistant pancreatic ductal adenocarcinoma (PDAC) tumours. This finding confirmed that targeting CDA in cancer cells or the UDP receptor in TAMs can counteract the tumour's immunosuppressive properties.
Broader Implications Across Cancer Types
Encouragingly, the team observed similar positive results in other types of cancer such as melanoma. This broad applicability suggests that inhibiting the CDA gene could enhance the effectiveness of immunotherapy across various resistant cancers.
Expert Insights and Future Directions
Massimiliano Mazzone highlighted the significance of the study, stating, "The results of this study are very positive to say the least. Not only does this propose a new potential target to enable immunotherapy in resistant cancer types, but it also improves our understanding of what drives immunosuppression in tumours. PDAC is one of the deadliest cancers out there. While our results give hope, more research is needed before we can bring this to the patient."
This groundbreaking research opens new avenues for enhancing the efficacy of immunotherapy in treating resistant cancers. By targeting the mechanisms that enable tumours to suppress the immune system, scientists are paving the way for more effective treatments. However, as Mazzone emphasized, further research is essential to translate these findings into practical therapies for patients. This study not only provides hope for those battling some of the most aggressive cancers but also deepens our understanding of tumour immunology.
. . .
References: